74 unrelated optic neuropathy patients were enrolled in the study. 62 of these initially underwent OPA1 genetic testing using Sanger sequencing (NM_130837.2) and OPA1 MLPA (Multiplex Ligation-dependent Probe Amplification). 38 of the 41 patients without mutations identified by OPA1 sequencing and MLPA were taken forward for Genetic Eye Disease (GEDi) next-generation sequencing (NGS) testing (sufficient DNA for GEDi testing was not available for 3 patients). Additionally, 12 patients underwent GEDi testing directly, as well as OPA1 MLPA. After testing was completed OPA1 mutations were identified in 24 patients (point mutations and CNVs) and a mitochondrial DNA mutation associated with Leber Hereditary Optic Neuropathy (LHON; m.11778G>A) was identified in one patient. Mutations in OPA3 and WFS1 were not identified in this cohort. To access the data, click or select the words “Appendix 1”.